Objetivo The human plasma proteome holds the promise of a revolution in disease diagnosis and therapy. One major breakthrough should come from the detection of multiprotein disease markers including isoforms. We propose to integrate a full proteomics analysis chain, from blood sample to the diagnosis information, combining bio-, nano, and information-related technologies. It includes an innovative patented lab-on-chip developed at CEA. The clinical application is early pancreatic cancer diagnosis.The project is based on a panel of 3 identified proteins, a protein isolation protocol, an optimised chromatographic-electrospray lab-on-chip, an Integrated Clinico-Proteomics Environment including a Proteomic Information Management System, a Clinical Information System, and modules for preprocessing, reconstruction, visualisation, protein identification, data mining and knowledge discovery. The clinical validation is applied to a cohort of 92 patients. Our targeted performance is to get at least the sensitivity of an orthogonal ELISA approach, to operate the analysis chain in less than 12 hours, and to demonstrate the interest of multiprotein marker.The main research outcomes will be an optimised chromatographic-electrospray lab-on-chip, a software environment supporting the integrated device, a proof-of-concept of their application to protein profiling for cancer diagnosis and an exploitation plan. The roadmap of this 36 months project is defined according to three main milestones: 1) at month 12, a first protein profile using a first version of the lab-on-chip on artificial samples is available, 2) at month 24, all the final versions of the sub-systems are ready for integration and validation, 3) at month 33, the validation on clinical samples is completed.The consortium partnership involves partners over 5 countries, combining basic and applied research (CEA, FORTH, SIB, WWU), 1 large company (ATOS) and 2 SMEs (BVN, GB), including clinicians and end-users (WWU, BVN). Ámbito científico natural sciencesbiological sciencesbiochemistrybiomoleculesproteinsproteomicsengineering and technologyother engineering and technologiesmicrotechnologylab on a chipnatural sciencescomputer and information sciencesdata sciencedata miningsocial sciencespolitical sciencespolitical transitionsrevolutionsmedical and health sciencesclinical medicineoncologypancreatic cancer Palabras clave Nanotechnology Programa(s) FP6-IST - Information Society Technologies: thematic priority under the specific programme "Integrating and strengthening the European research area" (2002-2006). Tema(s) IST-2005-2.5.2 - Micro/nano based sub-systems Convocatoria de propuestas Data not available Régimen de financiación STREP - Specific Targeted Research Project Coordinador ATOS ORIGIN SOCIEDAD ANONIMA ESPANOLA Aportación de la UE Sin datos Dirección CALLE DE ALBARRACIN 25 28037 MADRID España Ver en el mapa Coste total Sin datos Participantes (6) Ordenar alfabéticamente Ordenar por aportación de la UE Ampliar todo Contraer todo COMMISSARIAT A L'ENERGIE ATOMIQUE Francia Aportación de la UE Sin datos Dirección 31-33 RUE DE LA FEDERATION 75752 PARIS CEDEX 15 Ver en el mapa Coste total Sin datos DIGILAB BIOVISION GMBH Alemania Aportación de la UE Sin datos Dirección FEODOR-LYNEN-STRASSE 5 30625 HANNOVER Ver en el mapa Coste total Sin datos FOUNDATION FOR RESEARCH AND TECHNOLOGY - HELLAS Grecia Aportación de la UE Sin datos Dirección VASSILIKA VOUTON 17671 IRAKLIO, CRETE Ver en el mapa Coste total Sin datos GENEVA BIOINFORMATICS (GENEBIO) SA Suiza Aportación de la UE Sin datos Dirección AVENUE DE CHAMPEL 25 GENEVE Ver en el mapa Coste total Sin datos INSTITUT SUISSE DE BIOINFORMATIQUE Suiza Aportación de la UE Sin datos Dirección CMU, MICHEL-SERVET 1 1211 GENEVE Ver en el mapa Coste total Sin datos WESTFAELISCHE WILHELMS-UNIVERSITAET MUENSTER Alemania Aportación de la UE Sin datos Dirección SCHLOSSPLATZ 2 MUENSTER Ver en el mapa Enlaces Sitio web Opens in new window Coste total Sin datos